問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chung Shan Medical University Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 402Taichung CityTaichung South

Recruiting Trial

175Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

496Cases

2025-11-01 - 2027-10-11

Phase I/II

Not yet recruiting
A randomized, double-blind, phase 1/2a trial was conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DB-2304 injection in healthy adult participants and participants with systemic lupus erythematosus or cutaneous lupus erythematosus.

  • Condition/Disease

    Systemic lupus erythematosus

  • Test Drug

    DB-2304

Participate Sites
4Sites

Recruiting4Sites

2025-11-19 - 2030-06-30

Phase II

Not yet recruiting
A phase 2 open-label trial of navicixizumab monotherapy in patients with platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

  • Condition/Disease

    Platinum-based therapy-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer

  • Test Drug

    Navicixizumab

Participate Sites
10Sites

Recruiting10Sites

2024-07-01 - 2030-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2026-03-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

2026-03-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

2024-06-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2025-08-01 - 2031-12-31

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2026-03-30 - 2027-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2003-10-01 - 2008-07-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

-

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

1 2 3 4 5 50
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB